Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Convalescent plasma (CP) is widely used to treat COVID-19, but without formal evidence of efficacy. Here, we report the beneficial effects of CP in a severely ill COVID-19 patient with prolonged pneumonia and advanced chronic lymphocytic leukemia (CLL), who was unable to generate an antiviral antibody response of her own. On day 33 after becoming symptomatic, the patient received CP containing high-titer (ID > 5,000) neutralizing antibodies (NAbs), defervesced, and improved clinically within 48 h and was discharged on day 37. Hence, when present in sufficient quantities, NAbs to SARS-CoV-2 have clinical benefit even if administered relatively late in the disease course. However, analysis of additional CP units revealed widely varying NAb titers, with many recipients exhibiting endogenous NAb responses far exceeding those of the administered units. To obtain the full therapeutic benefits of CP immunotherapy, it will thus be important to determine the neutralizing activity in both CP units and transfusion candidates.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817775PMC
http://dx.doi.org/10.1016/j.xcrm.2020.100164DOI Listing

Publication Analysis

Top Keywords

covid-19 patient
8
convalescent plasma-mediated
4
plasma-mediated resolution
4
resolution covid-19
4
patient humoral
4
humoral immunodeficiency
4
immunodeficiency convalescent
4
convalescent plasma
4
plasma treat
4
treat covid-19
4

Similar Publications

Aim: To explore nursing students' satisfaction levels of each specific item and perceptions under the unprecedented abrupt online clinical practicum during the COVID-19 pandemic.

Design: A mixed-method design comprises a questionnaire and qualitative content analysis.

Methods: The study used purposive sampling using data from nursing students in grade 3 of a 4-year bachelor RN programme at a technological university in the north of Taiwan, compiled from May 2021 to June 2021 using an online questionnaire.

View Article and Find Full Text PDF

Background: Disparities in posttransplant outcomes persist and worsened during the COVID-19 pandemic, disproportionately affecting individuals with social risk factors. This study examined the total and residual (ie, direct) associations between individual- and neighborhood-level income and posttransplant outcomes among deceased donor kidney transplant (DDKT) and living donor kidney transplant recipients transplanted in the United States in 2020.

Methods: This retrospective cohort study linked Organ Procurement and Transplantation Network data with estimated individual annual income from LexisNexis and neighborhood median annual household income from the American Community Survey.

View Article and Find Full Text PDF

Introduction: The high mortality of Coronavirus Disease 2019 (COVID-19) highlights the need for safe and effective antiviral treatment. Small molecular antivirals (remdesivir, molnupiravir, nirmatrelvir/ritonavir) and immunomodulators (baricitinib, tocilizumab) have been developed or repurposed to suppress viral replication and ameliorate cytokine storms, respectively. Despite U.

View Article and Find Full Text PDF

Clinical Relevance: Dry eye disease (DED) is associated with use of video screen based gadgets and long hours spent looking through microscopes. Use of 3D goggles to view 3D screens leads to eye strain and worsening of dry eye symptoms. It is important to identify and treat the symptoms in professions carrying a high risk of DED.

View Article and Find Full Text PDF

The clinical manifestations of atypical hemolytic uremic syndrome (aHUS) vary depending on the genetic background. A 19-year-old man with the C3 p.Asp1115Asn variant experienced 2 episodes of recurrent aHUS following respiratory tract infections caused by influenza and COVID-19.

View Article and Find Full Text PDF